NASDAQ:PTX - Pernix Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pernix Therapeutics Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.21 0.00 (0.00 %) (As of 02/24/2020 09:49 AM ET) Add Compare Today's Range$0.21Now: $0.21▼$0.2150-Day Range$0.03MA: $0.16▼$0.2152-Week Range$0.20Now: $0.21▼$3.30VolumeN/AAverage Volume3.04 million shsMarket Capitalization$3.00 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PTX Previous Symbol CUSIP71426V10 CIK1024126 Webhttp://www.pernixtx.com/ Phone800-793-2145Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio0.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$146.07 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($14.77) per share Price / Book-0.01Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-77,140,000.00 Net Margins-59.70% Return on EquityN/A Return on Assets-37.01%Miscellaneous EmployeesN/A Outstanding Shares14,510,000Market Cap$3.00 million Next Earnings DateN/A OptionableOptionable Receive PTX News and Ratings via Email Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter. Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions What is Pernix Therapeutics' stock symbol? Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX." Has Pernix Therapeutics been receiving favorable news coverage? Media headlines about PTX stock have trended negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pernix Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Pernix Therapeutics. Who are some of Pernix Therapeutics' key competitors? Some companies that are related to Pernix Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX). What other stocks do shareholders of Pernix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Great Basin Scientific (GBSN), Catalyst Pharmaceuticals (CPRX), Immune Pharmaceuticals (IMNP), Amira Nature Foods (ANFI) and NovaBay Pharmaceuticals (NBY). Who are Pernix Therapeutics' key executives? Pernix Therapeutics' management team includes the folowing people: Mr. John Anthony Sedor, Chairman & CEO (Age 74)Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 60)Mr. Glenn Whaley, VP of Fin., Principal Financial & Accounting Officer (Age 51)Mr. Anthony M. Orrico, VP of Technical & Supply OperationsMr. George P. Jones, VP of Sales & Marketing What is Pernix Therapeutics' stock price today? One share of PTX stock can currently be purchased for approximately $0.21. How big of a company is Pernix Therapeutics? Pernix Therapeutics has a market capitalization of $3.00 million and generates $146.07 million in revenue each year. View Additional Information About Pernix Therapeutics. What is Pernix Therapeutics' official website? The official website for Pernix Therapeutics is http://www.pernixtx.com/. How can I contact Pernix Therapeutics? Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected] MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 350 (Vote Outperform)Underperform Votes: 242 (Vote Underperform)Total Votes: 592MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: Municipal Bonds
